Search Results

Your search for Richard L. Schilsky, MD, FACP, FASCO matches 2 pages

Showing 1 - 2

By The ASCO Post Staff / Thursday, January 31, 2019 2:57 PM

ASCO Clinical Cancer Advances 2019 Names Advance of the Year: Progress in Treating Rare Cancers

Over the past year, major research advances provided new treatment options for patients with rare, difficult-to-treat cancers. In recognition of these achievements, ASCO named “Progress in Treating Rare Cancers” as the Advance of the Year. To continue the forward momentum, ASCO also...

solid tumors

lymphoma

multiple myeloma

By The ASCO Post Staff / 2017 ASCO Annual Meeting / Wednesday, June 7, 2017 10:15 AM

ASCO's TAPUR Study Continues Its Expansion of Sites, Participants, and Collaborators

ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study continues to expand and now has more than 300 participants enrolled on study drug, more than 100 sites, new partnerships, and a revised protocol to lower the age of eligibility. “We are very pleased with the...

Apr

Today In Oncology

Search Results

Your search for Richard L. Schilsky, MD, FACP, FASCO matches 2 pages

ASCO Clinical Cancer Advances 2019 Names Advance of the Year: Progress in Treating Rare Cancers

ASCO's TAPUR Study Continues Its Expansion of Sites, Participants, and Collaborators

Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

Induction and Concurrent Vismodegib With Radiation Therapy for Locally Advanced Unresectable Basal Cell Carcinoma

FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non–Muscle Invasive Bladder Cancer

Predicting Ovarian Cancer Relapse With Spatial Tissue Analysis

Chemohormonal Therapy for Locally Advanced Prostate Cancer